Skip to main content
Top
Published in: Diabetologia 10/2006

01-10-2006 | Short communication

Circulating ghrelin concentrations are lowered by intracerebroventricular insulin

Authors: M. Ueno, J. B. C. Carvalheira, R. L. G. S. Oliveira, L. A. Velloso, M. J. A. Saad

Published in: Diabetologia | Issue 10/2006

Login to get access

Abstract

Aims/hypothesis

Ghrelin is a peptide that is mainly produced by the stomach and stimulates food intake, adiposity and weight gain. Previous studies have documented that plasma levels of ghrelin are reduced by insulin, but the mechanisms that mediate this effect are unclear.

Methods

To determine whether phosphatidylinositol 3-kinase (PI(3)K) and/or mitogen-activated protein kinase (MAPK) are involved in this insulin action, we tested the intracerebroventricular (i.c.v.) effect of specific inhibitors of PI(3)K (LY294002 and wortmannin) and MAPK (PD98059 and UO126) on the insulin-mediated reduction of ghrelin levels in rats.

Results

Intracerebroventricular treatment with insulin reduced ghrelin levels. Inhibition of PI(3)K specifically blocked the insulin-induced reduction in ghrelin concentration, whereas inhibition of MAPK had no effect on insulin-mediated actions. Moreover, pretreatment with i.c.v. PI(3)K inhibitors blocked the reduction of ghrelin levels after OGTT-induced hyperglycaemia and hyperinsulinaemia.

Conclusions/interpretation

These data demonstrate that changes in insulin action in the central nervous system regulate circulating ghrelin levels and that PI(3)K is a specific mediator of this action.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef
2.
go back to reference McCowen KC, Maykel JA, Bistrian BR, Ling PR (2002) Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. J Endocrinol 175:R7–R11PubMedCrossRef McCowen KC, Maykel JA, Bistrian BR, Ling PR (2002) Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. J Endocrinol 175:R7–R11PubMedCrossRef
3.
go back to reference Carvalheira JB, Ribeiro EB, Araujo EP et al (2003) Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats. Diabetologia 46:1629–1640PubMedCrossRef Carvalheira JB, Ribeiro EB, Araujo EP et al (2003) Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats. Diabetologia 46:1629–1640PubMedCrossRef
4.
go back to reference Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806PubMedCrossRef Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806PubMedCrossRef
5.
go back to reference Ueno M, Carvalheira JB, Tambascia RC et al (2005) Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 48:506–518PubMedCrossRef Ueno M, Carvalheira JB, Tambascia RC et al (2005) Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 48:506–518PubMedCrossRef
6.
go back to reference Mohlig M, Koebnick C, Weickert MO et al (2005) Arabinoxylan-enriched meal increases serum ghrelin levels in healthy humans. Horm Metab Res 37:303–308PubMedCrossRef Mohlig M, Koebnick C, Weickert MO et al (2005) Arabinoxylan-enriched meal increases serum ghrelin levels in healthy humans. Horm Metab Res 37:303–308PubMedCrossRef
7.
go back to reference Erdmann J, Topsch R, Lippl F, Gussmann P, Schusdziarra V (2004) Postprandial response of plasma ghrelin levels to various test meals in relation to food intake, plasma insulin, and glucose. J Clin Endocrinol Metab 89:3048–3054PubMedCrossRef Erdmann J, Topsch R, Lippl F, Gussmann P, Schusdziarra V (2004) Postprandial response of plasma ghrelin levels to various test meals in relation to food intake, plasma insulin, and glucose. J Clin Endocrinol Metab 89:3048–3054PubMedCrossRef
8.
go back to reference Saad MF, Bernaba B, Hwu CM et al (2002) Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 87:3997–4000PubMedCrossRef Saad MF, Bernaba B, Hwu CM et al (2002) Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 87:3997–4000PubMedCrossRef
9.
go back to reference Caixas A, Bashore C, Nash W, Pi-Sunyer F, Laferrere B (2002) Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab 87:1902PubMedCrossRef Caixas A, Bashore C, Nash W, Pi-Sunyer F, Laferrere B (2002) Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab 87:1902PubMedCrossRef
10.
go back to reference Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A (2003) Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 52:16–20PubMedCrossRef Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A (2003) Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 52:16–20PubMedCrossRef
11.
go back to reference Wortley KE, del Rincon JP, Murray JD et al (2005) Absence of ghrelin protects against early-onset obesity. J Clin Invest 115:3573–3578PubMedCrossRef Wortley KE, del Rincon JP, Murray JD et al (2005) Absence of ghrelin protects against early-onset obesity. J Clin Invest 115:3573–3578PubMedCrossRef
12.
go back to reference Zigman JM, Nakano Y, Coppari R et al (2005) Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115:3564–3572PubMedCrossRef Zigman JM, Nakano Y, Coppari R et al (2005) Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115:3564–3572PubMedCrossRef
13.
go back to reference Date Y, Kojima M, Hosoda H et al (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261PubMedCrossRef Date Y, Kojima M, Hosoda H et al (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261PubMedCrossRef
Metadata
Title
Circulating ghrelin concentrations are lowered by intracerebroventricular insulin
Authors
M. Ueno
J. B. C. Carvalheira
R. L. G. S. Oliveira
L. A. Velloso
M. J. A. Saad
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0371-8

Other articles of this Issue 10/2006

Diabetologia 10/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.